PriceTargets.com logo

Medical Properties Trust - MPW Stock Price Target and Predictions

  • Consensus Rating: Reduce
  • Consensus Price Target: $5.75
  • Forecasted Upside: 14.89%
  • Number of Analysts: 13
  • Breakdown:
  • 4 Sell Ratings
  • 7 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$5.01 As of 05/17/2024 01:00 AM ET
▼ -0.12 (-2.34%)

This chart shows the closing price for MPW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Medical Properties Trust Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MPW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MPW

Analyst Price Target is $5.75
▲ +14.89% Upside Potential
This price target is based on 13 analysts offering 12 month price targets for Medical Properties Trust in the last 3 months. The average price target is $5.75, with a high forecast of $10.00 and a low forecast of $4.00. The average price target represents a 14.89% upside from the last price of $5.01.

This chart shows the closing price for MPW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Reduce

The current consensus among 13 investment analysts is to reduce stock in Medical Properties Trust. This Reduce consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
11/24/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
2/22/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
5/23/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
8/21/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
11/19/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
2/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
4/17/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings
Ratings as of
5/17/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 4 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$5.00Low
4/17/2024Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold$2.00 ➝ $5.00Low
4/10/2024Colliers SecuritiesDowngradeBuy ➝ Neutral$10.00 ➝ $4.25Low
4/8/2024Truist FinancialBoost TargetHold ➝ Hold$4.00 ➝ $4.50Low
3/1/2024BNP ParibasUpgradeNeutral ➝ Outperform$6.00Low
2/20/2024Royal Bank of CanadaLower TargetOutperform ➝ Outperform$8.00 ➝ $5.00Low
1/30/2024Deutsche Bank AktiengesellschaftInitiated CoverageSell$2.00Low
1/5/2024KeyCorpReiterated RatingOverweight ➝ Sector WeightLow
1/3/2024MizuhoLower TargetNeutral ➝ Neutral$9.00 ➝ $7.00Low
11/29/2023JPMorgan Chase & Co.Lower TargetUnderweight ➝ Underweight$8.00 ➝ $5.00Low
11/10/2023Stifel NicolausDowngradeBuy ➝ Hold$12.00 ➝ $4.50Low
10/16/2023Wells Fargo & CompanyDowngradeEqual Weight ➝ Underweight$7.00 ➝ $4.00Low
10/11/2023BNP ParibasInitiated CoverageNeutral$5.50Low
9/29/2023Truist FinancialLower Target$10.00 ➝ $6.00Low
9/25/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$10.00Low
8/31/2023MizuhoDowngradeBuy ➝ Neutral$18.00 ➝ $9.00Low
8/22/2023BarclaysLower TargetOverweight ➝ Overweight$12.00 ➝ $10.00Low
8/21/2023JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$9.00 ➝ $7.00Low
8/14/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$12.00 ➝ $10.00Low
8/11/2023Raymond JamesDowngradeStrong-Buy ➝ UnderperformLow
8/11/2023Bank of AmericaDowngradeNeutral ➝ Underperform$9.00 ➝ $8.00Low
4/28/2023Stifel NicolausLower Target$14.00 ➝ $12.00Low
4/19/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$9.00Low
4/5/2023BarclaysLower TargetOverweight$14.00 ➝ $12.00Low
4/4/2023KeyCorpLower TargetOverweight$16.00 ➝ $15.00Low
3/31/2023Truist FinancialBoost Target$8.00 ➝ $9.00Low
3/29/2023Truist FinancialLower TargetHold$14.00 ➝ $8.00Low
3/16/2023Bank of AmericaDowngradeBuy ➝ Neutral$10.00Low
3/7/2023Credit Suisse GroupReiterated RatingNeutral$11.00Low
3/3/2023JPMorgan Chase & Co.Lower TargetNeutral$14.00 ➝ $12.00Low
3/2/2023Raymond JamesLower TargetStrong-Buy$18.00 ➝ $16.00Low
2/27/2023BarclaysLower TargetOverweight$17.00 ➝ $14.00Low
2/24/2023Credit Suisse GroupLower TargetNeutral$13.00 ➝ $11.00Low
1/27/2023BarclaysLower TargetOverweight$19.00 ➝ $17.00Low
1/19/2023KeyCorpLower TargetOverweight$18.00 ➝ $16.00Low
1/17/2023Credit Suisse GroupBoost TargetNeutral$11.00 ➝ $13.00Low
12/21/2022Credit Suisse GroupLower TargetNeutral$17.00 ➝ $11.00Low
12/2/2022MizuhoLower Target$20.00 ➝ $18.00Low
11/14/2022Bank of AmericaUpgradeNeutral ➝ Buy$13.00 ➝ $16.00Low
10/21/2022BarclaysLower TargetOverweight$23.00 ➝ $19.00Low
10/4/2022Royal Bank of CanadaLower Target$20.00 ➝ $18.00Low
9/22/2022Raymond JamesLower TargetStrong-Buy$20.00 ➝ $18.00Low
9/16/2022Deutsche Bank AktiengesellschaftLower TargetHold$17.00 ➝ $15.00Low
8/4/2022BarclaysLower TargetOverweight$27.00 ➝ $23.00N/A
7/29/2022MizuhoLower TargetBuy$26.00 ➝ $20.00Low
7/14/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral$23.00 ➝ $17.00Low
7/13/2022Deutsche Bank AktiengesellschaftLower TargetHold$20.00 ➝ $17.00Low
7/11/2022Truist FinancialLower Target$23.00 ➝ $18.00N/A
7/7/2022KeyCorpLower TargetOverweight$23.00 ➝ $18.00N/A
6/30/2022Jefferies Financial GroupLower TargetHold$19.00 ➝ $15.00Low
6/22/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$24.00 ➝ $18.00Low
4/27/2022Deutsche Bank AktiengesellschaftLower Target$25.00 ➝ $20.00High
4/22/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$25.00 ➝ $20.00High
3/24/2022Truist FinancialLower TargetHold$26.00 ➝ $23.00Low
3/11/2022Bank of AmericaDowngradeBuy ➝ Neutral$21.00Medium
2/14/2022Credit Suisse GroupLower TargetOutperform$27.00 ➝ $26.00High
2/1/2022Credit Suisse GroupInitiated CoverageOutperformLow
1/20/2022MizuhoBoost Target$23.00 ➝ $26.00High
1/3/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$27.00 ➝ $25.00Low
10/29/2021Raymond JamesBoost TargetStrong-Buy$25.00 ➝ $26.00Medium
10/27/2021Bank of AmericaUpgradeNeutral ➝ Buy$21.50 ➝ $24.00High
10/25/2021Raymond JamesInitiated CoverageStrong-Buy$25.00Medium
8/11/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$23.00Low
7/14/2021MizuhoReiterated RatingBuy$23.00Low
7/6/2021Bank of AmericaDowngradeBuy ➝ Neutral$21.50Low
6/14/2021Wolfe ResearchInitiated CoveragePeer Perform$23.00High
6/3/2021Deutsche Bank AktiengesellschaftBoost TargetBuy$25.00 ➝ $27.00Medium
5/10/2021Royal Bank of CanadaReiterated RatingOutperform ➝ Sector Perform$24.00 ➝ $23.00Low
5/3/2021Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$24.00 ➝ $23.00Medium
2/8/2021BarclaysBoost TargetOverweight$23.00 ➝ $25.00Medium
1/22/2021Truist FinancialDowngradeBuy ➝ Hold$21.00 ➝ $22.00Low
1/21/2021KeyCorpBoost TargetOverweight$22.00 ➝ $24.00Medium
12/15/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$24.00Medium
11/27/2020Truist FinancialBoost Target$20.00 ➝ $21.00Low
9/9/2020Colliers SecuritiesInitiated CoverageBuy$23.00Low
9/1/2020Stifel NicolausReiterated RatingBuy$21.00Low
8/24/2020MizuhoUpgradeNeutral ➝ Buy$20.00 ➝ $23.00Low
7/10/2020Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$23.00 ➝ $19.00Medium
6/25/2020SunTrust BanksBoost TargetBuy$19.00 ➝ $20.00Medium
4/23/2020SunTrust BanksLower TargetBuy$22.00 ➝ $19.00Low
4/21/2020KeyCorpLower TargetOverweight$25.00 ➝ $20.00High
4/3/2020Wells Fargo & CompanyLower TargetEqual Weight$21.00 ➝ $16.00Low
4/3/2020JPMorgan Chase & Co.Lower TargetOverweight$25.00 ➝ $20.00High
3/30/2020MizuhoDowngradeBuy ➝ Neutral$27.00 ➝ $19.00Low
3/23/2020Bank of AmericaUpgradeNeutral ➝ BuyHigh
3/18/2020BarclaysReiterated RatingBuy$22.00Medium
3/9/2020Royal Bank of CanadaReiterated RatingBuy$25.00Medium
1/16/2020KeyCorpBoost TargetOverweight$22.00 ➝ $23.00Medium
1/14/2020Robert W. BairdBoost TargetNeutral$20.00 ➝ $22.00Low
12/26/2019MizuhoBoost TargetBuy$25.00 ➝ $26.00Low
12/19/2019MizuhoInitiated CoverageBuy$25.00Medium
10/21/2019BarclaysSet TargetBuy$22.00Low
10/14/2019Bank of AmericaInitiated CoverageNeutral$19.50Low
9/12/2019Berenberg BankInitiated CoverageBuy$22.00Low
9/4/2019JPMorgan Chase & Co.Set TargetBuy$21.00Low
9/3/2019BarclaysInitiated CoverageOverweight$20.00High
8/27/2019SunTrust BanksBoost TargetBuy$20.00 ➝ $21.00High
8/12/2019Stifel NicolausSet TargetBuy$21.00Low
7/29/2019Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
7/23/2019Stifel NicolausUpgradeHold ➝ Buy$18.00 ➝ $19.00High
7/2/2019SunTrust BanksUpgradeHold ➝ Buy$19.00 ➝ $20.00High
(Data available from 5/18/2019 forward)

News Sentiment Rating

1.05 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 33 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 31 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 17 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/20/2023
  • 25 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
1/19/2024
  • 21 very positive mentions
  • 8 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
2/18/2024
  • 36 very positive mentions
  • 21 positive mentions
  • 8 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 48 very positive mentions
  • 14 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
4/18/2024
  • 60 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
5/18/2024

Current Sentiment

  • 60 very positive mentions
  • 18 positive mentions
  • 5 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Medical Properties Trust logo
Medical Properties Trust, Inc. is a self-advised real estate investment trust formed in 2003 to acquire and develop net-leased hospital facilities. From its inception in Birmingham, Alabama, the Company has grown to become one of the world's largest owners of hospital real estate with 441 facilities and approximately 44,000 licensed beds as of September 30, 2023. Since the end of the third quarter, the Company has sold four facilities and now owns approximately 43,000 licensed beds in nine countries across three continents. MPT's financing model facilitates acquisitions and recapitalizations and allows operators of hospitals to unlock the value of their real estate assets to fund facility improvements, technology upgrades and other investments in operations.
Read More

Today's Range

Now: $5.01
Low: $4.98
High: $5.21

50 Day Range

MA: $4.53
Low: $3.97
High: $5.84

52 Week Range

Now: $5.01
Low: $2.92
High: $10.74

Volume

19,009,049 shs

Average Volume

20,988,644 shs

Market Capitalization

$3.00 billion

P/E Ratio

N/A

Dividend Yield

11.72%

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Medical Properties Trust?

The following equities research analysts have issued reports on Medical Properties Trust in the last twelve months: Bank of America Co., Barclays PLC, BNP Paribas, Colliers Securities, Deutsche Bank Aktiengesellschaft, JPMorgan Chase & Co., KeyCorp, Mizuho, Raymond James, Royal Bank of Canada, Stifel Nicolaus, StockNews.com, TheStreet, Truist Financial Co., and Wells Fargo & Company.
View the latest analyst ratings for MPW.

What is the current price target for Medical Properties Trust?

11 Wall Street analysts have set twelve-month price targets for Medical Properties Trust in the last year. Their average twelve-month price target is $5.75, suggesting a possible upside of 14.9%. Barclays PLC has the highest price target set, predicting MPW will reach $10.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $4.00 for Medical Properties Trust in the next year.
View the latest price targets for MPW.

What is the current consensus analyst rating for Medical Properties Trust?

Medical Properties Trust currently has 4 sell ratings, 7 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Reduce."
View the latest ratings for MPW.

What other companies compete with Medical Properties Trust?

Other companies that are similar to Medical Properties Trust include Sabra Health Care REIT, EPR Properties, National Health Investors, Pebblebrook Hotel Trust and DiamondRock Hospitality. Learn More about companies similar to Medical Properties Trust.

How do I contact Medical Properties Trust's investor relations team?

Medical Properties Trust's physical mailing address is 1000 URBAN CENTER DRIVE SUITE 501, BIRMINGHAM AL, 35242. The real estate investment trust's listed phone number is (205) 969-3755 and its investor relations email address is [email protected]. The official website for Medical Properties Trust is www.medicalpropertiestrust.com. Learn More about contacing Medical Properties Trust investor relations.